Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH
RegulatoryapprovedCiprocopan Succinate TabletsPositive
AI Analysis
Summary
Haisco Pharmaceutical Group's Ciprocopan Succinate Tablets received marketing approval from China's National Medical Products Administration as a Class 1 innovative drug for treating paroxysmal nocturnal hemoglobinuria (PNH).
Outcome Details
Class 1 innovative drug marketing approval from National Medical Products Administration of China
Importance:8/10
Sentiment:
0.90
China approvalPNHClass 1 innovative drugNMPA
Read the original article
Published by PR Newswire Clinical Trials on July 23, 2026 6:08 AM